retatrutide nejm 2023 obesity trial ly3437943 🧬 R3TA is a next-generation peptide being studied for its unique triple-receptor approach to metabolic health. Unlike traditional GLP-1 therapies, R3TA is designed to interact with three metabolic pathways simultaneously: GLP-1, GIP Want to learn more about

This triggers a natural GH release without the common side effects associated with other GHRPs such as elevated cortisol, prolactin, or uncontrollable appetite

This dual action amplifies its effects on appetite regulation and glucose metabolism

The oral formulation may have different absorption characteristics that influence gastrointestinal tolerability. Saxenda (Liraglutide): Shows a 13% reduction in gastric emptying at the 1-hour mark with lower doses compared to semaglutide, potentially causing fewer burping issues Dose adjustments: Working with your healthcare provider to find the optimal dose that balances efficacy with tolerability can help manage side effects Other medications in the GLP-1 class may have different side effect profiles, and your healthcare provider can help determine the best option based on your individual response and health goals

Kalkan, I

A 2020 report in the Journal of the Endocrine Society indicated that dulaglutide (Trulicity) may cause small bowel obstruction